CAAS Capital Management’s Amedisys AMED Stock Holding History

CAAS Capital Management’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-6,000	Closed	-$501K	–	701
2022 Q4	$501K	Buy	+6,000	New	+$541K	0.03%	448

Other funds holding AMED

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

CAAS Capital Management's AMED Position: Q1 2023 in Review

CAAS Capital Management sold out of Amedisys (AMED) in Q1 2023, closing a stake of 6,000 shares — an estimated $501K sold.

CAAS Capital Management first reported a position in AMED in Q4 2022 and held it in 1 quarter. The position peaked at $501K in Q4 2022. 281 funds tracked by Wall St. Rank hold AMED as of Q1 2023.

CAAS Capital Management reported no remaining Amedisys position as of Q1 2023 after selling out during the quarter.
CAAS Capital Management sold 6,000 Amedisys shares in Q1 2023, an estimated $501K.
CAAS Capital Management first reported a position in Amedisys in Q4 2022 and held it in 1 quarter.
CAAS Capital Management's Amedisys position peaked at $501K in Q4 2022.
281 funds tracked by Wall St. Rank held Amedisys as of Q1 2023.

Based on CAAS Capital Management's 13F filing for Q1 2023, filed 15 May 2023.